TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11109978

Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg implants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of estradiol 50 mg and testosterone 100 mg
Number of subjects: 25
Study: 8924135

Group type: EXPERIMENTAL
Intervention: 400 micrograms salbutamol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 600 micrograms salbutamol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study: 1660011

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment, 1.5 x 10(6) IU subcutaneously three times for the first week followed by 3 x 10(6) IU three times weekly for a further 6 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo treatment, matching placebo injections.
Number of subjects: 120
Study: 6175136

Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream 1% (50 micrograms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Halcinonide cream (Halog) 0.1% (50 micrograms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Unguentum cetacei simplex (cold cream) (50 micrograms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Halcinonide cream base (rubbing)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 37
Study: 31094842

Group type: EXPERIMENTAL
Intervention: TT-TG distance measurement in PFI patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: TT-TG distance measurement in control patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comparison of TT-TG distance between PFI and control groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for TT-TG distance threshold
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Likelihood ratios for TT-TG distance threshold
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Increase in correct PFI diagnosis using TT-TG distance
Number of subjects: 48
Study: 28390807

Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation (XNI) for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI) for 30 days
Number of subjects: 30
Study: 26209543

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of MMF vs Placebo
Number of subjects: 52
Study: 23299002

Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Family connections and prosocial norms
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Peer prosocial norms
Number of subjects: 253
Study: 21989412

Group type: EXPERIMENTAL
Intervention: TERT572
Number of subjects: 48

Group type: COMPARATOR
Intervention: TERT572Y
Number of subjects: 48
Study: 19833274

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural analgesia (Group C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia alone (Group G)
Number of subjects: 40
Study: 17074108

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily for 4 weeks
Number of subjects: 87
Study: 15001263

Group type: EXPERIMENTAL
Intervention: RT preceded by chemotherapy (vincristine, etoposide, carboplatin, cyclophosphamide)
Number of subjects: 179

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: RT completed within 50 days
Number of subjects: 179

Group type: COMPARATOR
Intervention: RT completed in more than 50 days
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Patients with PF targeting deviation
Number of subjects: 179

Group type: COMPARATOR
Intervention: Patients without PF targeting deviation
Number of subjects: 179
Study: 11157465

Group type: EXPERIMENTAL
Intervention: Drop squat exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Leg extension/leg curl exercises
Number of subjects: 19
Study: 9216554

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8091242

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy with drugs like 5-fluorouracil (5-FU), mitomycin, doxorubicin, and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU-containing combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single agents (5-FU and mitomycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 5-FU with radiation therapy
Number of subjects: 0
Study: 3405343

Group type: EXPERIMENTAL
Intervention: Combined therapy (adjuvant chemotherapy with cyclophosphane, methotrexate, 5‐fluorouracil)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 720
Study: 31915895

Group type: EXPERIMENTAL
Intervention: Oral sodium butyrate (4 g daily for 1 month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31070609

Group type: EXPERIMENTAL
Intervention: Nattokinase supplementation
Number of subjects: 50
Study: 29284448

Group type: EXPERIMENTAL
Intervention: Experience Sampling Method Intervention (ESM-I) consisting of six weeks of ESM combined with weekly feedback regarding the individual's positive affective experiences
Number of subjects: 101

Group type: COMPARATOR
Intervention: Experience Sampling Method without feedback
Number of subjects: 101

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 101
Study: 25387855

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 22132711

Group type: EXPERIMENTAL
Intervention: 4-mg intravitreal injections of triamcinolone acetonide (IVTA); 21 patients in the IVTA group
Number of subjects: 43

Group type: COMPARATOR
Intervention: 1.25-mg intravitreal injections of bevacizumab (IVB); 22 patients in the IVB group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (IVTA)
Number of subjects: 43
Study: 21607794

Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg by mouth three times a day starting on postoperative day 1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimal amount of water
Number of subjects: 30
Study: 18485172

Group type: EXPERIMENTAL
Intervention: 1000 micrograms of self-administered vaginal misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered vaginal placebo
Number of subjects: 0
Study: 16170522

Group type: EXPERIMENTAL
Intervention: Flicker light provocation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline measurement and flicker light provocation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Follow-up examinations
Number of subjects: 28
Study: 12930165

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g Cr.kg(‐1) body mass for 5 days, followed by 2.25 g Cr for 9 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10737689

Group type: EXPERIMENTAL
Intervention: Fit & Firm (moderate-intensity endurance and strengthening exercises)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Stretch & Flex (stretching and flexibility exercises)
Number of subjects: 103
Study: 9362855

Group type: EXPERIMENTAL
Intervention: Early bath
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late bath
Number of subjects: 200
Study: 1545849

Group type: EXPERIMENTAL
Intervention: Erythropoietin (36 units per kilogram of body weight three times weekly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythropoietin (18 units per kilogram three times weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with pruritus
Number of subjects: 20
Study: 4037908

Group type: EXPERIMENTAL
Intervention: Tube-Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tube-Cimetidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: No Tube-Placebo
Number of subjects: 200

Group type: COMPARATOR
Intervention: No Tube-Cimetidine
Number of subjects: 200
Study: 31965179

Group type: EXPERIMENTAL
Intervention: l-Leucine (192 mg/kg body mass) administered daily for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no leucine supplementation)
Number of subjects: 24
Study: 31612956

Group type: EXPERIMENTAL
Intervention: Cannabis co-use
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Alcohol co-use
Number of subjects: 157

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 157
Study: 29887998

Group type: EXPERIMENTAL
Intervention: Active commuting (BIKE, n=19)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of moderate intensity (MOD, n=31)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of vigorous intensity (VIG, n=24)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Habitual lifestyle (CON, n=16)
Number of subjects: 90
Study: 27563630

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT), one session per week for 4 weeks, using focus probe with varying energy levels (0.05, 0.07, 0.1, and 0.15) and shock numbers (800, 900, 1000, and 1100) from the first to the fourth session.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative treatment including wrist splint at night for 3 months, nonsteroidal anti-inflammatory drugs for 2 weeks, and oral Vitamin B1 for a month.
Number of subjects: 60
Study: 25091879

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Physical activity (increased or maintained)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 683
Study: 22249153

Group type: EXPERIMENTAL
Intervention: Remifentanil IVPCA
Number of subjects: 39

Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 39
Study: 21171756

Group type: EXPERIMENTAL
Intervention: Emotional reappraisal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expressive suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-regulation
Number of subjects: 0
Study: 17629590

Group type: EXPERIMENTAL
Intervention: 50mg MMPD q12h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 25mg MMPD q12h
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 15610942

Group type: EXPERIMENTAL
Intervention: Catatonia group (n=72; 32% of total)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Noncatatonic group
Number of subjects: 225
Study: 11893235

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B 10,000U
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B 2500 to 10,000U
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 0
Study: 10442065

Group type: EXPERIMENTAL
Intervention: Quinine salts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 7608225

Group type: EXPERIMENTAL
Intervention: Decompression with laminotomy and medial facetectomy (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Decompression and arthrodesis of the most stenotic segment (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Decompression and arthrodesis of all decompressed vertebral segments (Group III)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of pain relief between Group I and Group II
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of pain relief between Group II and Group III
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of pain relief between Group I and Group III
Number of subjects: 45
Study: 2145645

Group type: EXPERIMENTAL
Intervention: Intravenous colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 0
Study: 406626

Group type: EXPERIMENTAL
Intervention: Marijuana extract calibrated to 0.3 mg/kg delta‐9‐tetrahydrocannabinol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 16
Study: 31097078

Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU (up to 12 sessions delivered within 16 weeks)
Number of subjects: 230

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU (subgroup analysis for those widowed, divorced or separated)
Number of subjects: 230

Group type: COMPARATOR
Intervention: TAU (subgroup analysis for those widowed, divorced or separated)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU
Number of subjects: 230
Study: 28108424

Group type: EXPERIMENTAL
Intervention: Multilevel cervical total disk replacement (MCTDR)
Number of subjects: 24
Study: 25736132

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted rectal cancer resection using ENDO RLC general endoscopic linear cutter and single-use loading unit and circular staplers from REACH medical equipment co.LTD
Number of subjects: 64

Group type: COMPARATOR
Intervention: Surgery with corresponding products widely used (from Johnson and Johnson Medical Equipment C.Ltd)
Number of subjects: 64
Study: 23608971

Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy initiation
Number of subjects: 90
Study: 21762269

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy for 14 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy for 10 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy for 14 days
Number of subjects: 417

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy for 10 days
Number of subjects: 417
Study: 19725861

Group type: EXPERIMENTAL
Intervention: Cryopreserved aortic homograft (CH)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prototype stentless bioprosthesis (SS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Standard stented bioprosthesis (SD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study: 17767071

Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 mL/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6-8 mL/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tidal volume of 30 minutes duration at a rate of 15
Number of subjects: 40
Study: 15383198

Group type: EXPERIMENTAL
Intervention: Quetiapine (median dosage, 200 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Risperidone (median dosage, 3 mg/day)
Number of subjects: 92
Study: 11546721

Group type: EXPERIMENTAL
Intervention: New technique (NT) for positioning the LM-DLT by fibreoptic bronchoscopy (FOB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Classic technique (CT) for positioning the LM-DLT
Number of subjects: 61
Study: 9691901

Group type: EXPERIMENTAL
Intervention: Echo planar imaging (MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no in utero echo planar imaging exposure)
Number of subjects: 0
Study: 8165628

Group type: EXPERIMENTAL
Intervention: 2 g dried ginger
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2901018

Group type: COMPARATOR
Intervention: Placebo (hypertonic saline infusion of 1200 ml of 2.5% NaCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta-blockade)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blockade)
Number of subjects: 8
Study: 31865790

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure strategy (systolic blood pressure <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure strategy (systolic blood pressure <140 mm Hg)
Number of subjects: 9361
Study: 30009543

Group type: EXPERIMENTAL
Intervention: Enalapril (group A, n=44)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (group B, n=40)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Enalapril (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 84
Study: 26546403

Group type: EXPERIMENTAL
Intervention: 300 mg MgSO4 plus 40 mg lidocaine (Group M+L)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine (Group L)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 300 mg MgSO4 (Group M)
Number of subjects: 300
Study: 24700706

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with TAXUS Express paclitaxel-eluting stents
Number of subjects: 705

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 705
Study: 23244706

Group type: EXPERIMENTAL
Intervention: Intervention Group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study: 20569719

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) stimulation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Left ventricular (LV) stimulation
Number of subjects: 176
Study: 19046178

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N(2)O)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study: 15754197

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam prophylaxis (3 g every 6 h for 3 days) plus standard treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 100
Study: 12414200

Group type: EXPERIMENTAL
Intervention: Endovascular treatment by detachable platinum coils
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2143
Study: 10334615

Group type: EXPERIMENTAL
Intervention: Brief physician advice (two 10- to 15-minute counseling sessions)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 8564099

Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Misoprostol (PGE1-analogue)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 2% Ethanol
Number of subjects: 23
Study: 1919626

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 years)
Number of subjects: 1846
Study: 6313029

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 3 months and 150 mg at night for 9 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study: 31752517

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study: 29878650

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion continued for 24 hours postpartum
Number of subjects: 1113

Group type: COMPARATOR
Intervention: No magnesium sulphate infusion (stopped immediately after delivery)
Number of subjects: 1113
Study: 27275843

Group type: EXPERIMENTAL
Intervention: Urocortin 2 (36-360 pmol min(-1))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urocortin 3 (1.2-12 nmol min(-1))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol min(-1))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (573-5730 pmol kg(-1) min(-1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study: 25187049

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) daily practice
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 67
Study: 22258203

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: State Entropy (SE)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Type 1 Discrepancies (DR)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Type 2 Discrepancies (DR)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Electrode Position
Number of subjects: 102
Study: 20036147

Group type: EXPERIMENTAL
Intervention: Cuffed SBCC (n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Noncuffed SBCC (n = 42)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cuffed SBCC
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both Cuffed and Noncuffed SBCCs
Number of subjects: 84
Study: 17347862

Group type: EXPERIMENTAL
Intervention: Three sessions of constant low-energy treatment (0.08 mJ/mm(2); 1000 impulses) without local anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two middle-energy treatments (0.2 mJ/mm(2); 2000 impulses) with subacromial anesthesia
Number of subjects: 50
Study: 17006287

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine alone (dose 1)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine alone (dose 2)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine concomitantly with other vaccines
Number of subjects: 617
Study: 14608267

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) and Lactobacillus sporogenes preparation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11071838

Group type: EXPERIMENTAL
Intervention: SunSafe multicomponent, community‐based intervention
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Control towns
Number of subjects: 1490
Study: 8930233

Group type: EXPERIMENTAL
Intervention: Yogurt containing live Lactobacillus acidophilus (150 mL daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pasteurized yogurt
Number of subjects: 46
Study: 1422689

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 277

Group type: COMPARATOR
Intervention: Orchiectomy alone
Number of subjects: 277

Group type: COMPARATOR
Intervention: Combined therapy (orchiectomy + radiotherapy)
Number of subjects: 277
Study: 6334435

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 50